CJC-1295 no DAC 10 mg
CJC-1295 without DAC, commonly described as Modified GRF (1-29), is a short-acting GHRH analogue studied for pituitary signalling, growth-hormone pulses and peptide stability.
Why do researchers study CJC-1295 no DAC?
GHRH receptor
Research into the receptor that controls the pituitary release of growth hormone.
Short hormone signals
Studies designed around a shorter period of receptor stimulation.
Growth-hormone pulses
Research into the timing and pattern of the body’s GH response.
Peptide stability
Four amino-acid substitutions help protect the sequence from rapid enzymatic breakdown.
What is CJC-1295 no DAC?
The material commonly called CJC-1295 without DAC is a 29-amino-acid peptide also known as Modified GRF (1-29). It is based on the active part of natural GHRH.
Unlike CJC-1295 with DAC, this form does not include the albumin-binding extension. It is therefore used when researchers want a shorter GHRH-like signal.
Understanding the biological signal
Modified GRF (1-29) activates the same main receptor as natural GHRH and encourages pituitary cells to release growth hormone.
Its four amino-acid substitutions improve stability compared with the natural 1-29 fragment, while the absence of DAC keeps it distinct from the long-acting albumin-bound form.
What have studies found?
Greater resistance to breakdown
Laboratory development of modified GHRH fragments showed that selected amino-acid substitutions can preserve receptor activity while improving stability.
Pituitary growth-hormone release
Modified GRF (1-29) is used to study cyclic-AMP signalling inside pituitary cells and the resulting release of growth hormone.
Short versus long action
The no-DAC peptide provides a direct comparison with albumin-binding CJC-1295, allowing researchers to isolate the effect of extended circulation time.
Timing of the GH response
Its shorter activity makes Modified GRF (1-29) useful in experiments focused on individual GH pulses and the timing of endocrine signals.
Selected research
- CJC-1295 without DAC compound recordChemical identity · PubChem
- Development of modified GHRH analoguesPeptide engineering research · PubMed
- CJC-1295 and growth-hormone pulse researchRelated GHRH-analogue pharmacology · PubMed
Product details at a glance
01Research areas⌄
CJC-1295 no DAC is studied in connection with GHRH-receptor signalling, short hormone signals, growth-hormone pulses and peptide stability.
02What the package contains⌄
One sealed laboratory vial containing 10 mg of freeze-dried CJC-1295 no DAC material, according to the selected product variant.
03Storage of the freeze-dried product⌄
Keep the sealed freeze-dried vial at −20 °C, dry and protected from light. Let the closed vial reach room temperature before opening to limit condensation.
04Handling a prepared laboratory solution⌄
After preparation with bacteriostatic water, keep refrigerated at 2–8 °C and protected from light. Do not freeze; minimize repeated warming and cooling.
05Why the vial can look almost empty⌄
10 mg is a small mass. After freeze-drying, the material can form a thin layer or compact deposit at the bottom of the vial and may appear smaller than expected.
Match the report to the vial
Available analytical results are organized by product and batch. Always compare the batch identifier in the report with the identifier on the vial label.
For laboratory and analytical research only. Not for human or veterinary use.
Reviews
There are no reviews yet.